伊立替康单药三线治疗晚期肺鳞癌临床观察

目的评价伊立替康单药三线治疗晚期肺鳞癌的有效性与安全性。方法 2007年12月至今就诊我院的23例晚期肺鳞癌患者,其中男17例,女6例,ECOG 0～1分,既往一、二线方案化疗无效,予CPT-11 180 mg.m-2静脉滴注第1天,每3周重复,化疗2周期后评价治疗的有效性,并记录治疗的安全性。结果 23例患者中有2例因第1周期治疗后出现严重骨髓抑制及腹泻退出研究,未能评价疗效。21例可评价病例中无CR患者,PR 9.5%(2/21),SD 38.1%(8/21),疾病控制率CR+PR+SD47.6%,最多者接受伊立替康单药化疗6周期,骨髓毒性是剂量限制性毒性,其他主要毒副反应为疲劳、腹泻、恶心呕吐等。结论伊立替康治疗难治性晚期肺鳞癌有一定的疾病控制率,安全性可以接受。

Irinotecan as 3rd line treatment for advanced lung squamous-cell carcinoma patients

Aim To evaluate the efficacy and side effects of irinotecan in advanced lung squamous-cell carcinoma patients as the 3rd line therapy.Methods The study was conducted on 23 advanced patients with lung squamous-cell carcinoma,who had failed to previous chemotherapy and all the patients had been confirmed with pathology or cytology.Among the 23 cases,male 17,female 6,ECOG 0～1,Patients received single agent regimen Irinotecan 180 mg·m-2 on day 1,with 21 days as one cycle.Results There were 2 patients who stayed out of the study because of side effects.There was no CR case,PR 9.5%,SD 38.1%,the disease control rate 47.6%.The common adverse events were leucopenia,diarrhoea,fatigue,gastrointestinal response.Conclusion Chemotherapy with irinotecan is effective and feasible for advanced lung squamous-cell carcinoma patients as the 3rd line therapy.